HER2 negative metastatic breast cancer
Clinical trials for HER2 negative metastatic breast cancer explained in plain language.
Never miss a new study
Get alerted when new HER2 negative metastatic breast cancer trials appear
Sign up with your email to follow new studies for HER2 negative metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could this drug help patients with Hard-to-Treat breast cancer?
Disease control Recruiting nowThis study tests a drug called trastuzumab deruxtecan (T-DXd) in 40 adults with advanced breast cancer that has no HER2 protein (HER2-0). Participants get the drug every 3 weeks. The goal is to see if it shrinks tumors and which patients benefit most.
Matched conditions: HER2 NEGATIVE METASTATIC BREAST CANCER
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Real-world study examines breast cancer drug's effectiveness outside clinical trials
Knowledge-focused Recruiting nowThis study will review medical records of 200 patients in China with HER2-negative metastatic breast cancer who received sacituzumab govitecan. Researchers want to see how long the drug keeps cancer from growing and how well patients tolerate it. The goal is to understand real-wo…
Matched conditions: HER2 NEGATIVE METASTATIC BREAST CANCER
Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC